The success of atezolizumab plus bevacizumab treatment contributed to a shift in systemic
therapies for hepatocellular carcinoma (HCC) towards combinations that include cancer …

Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC …

Hepatocellular carcinoma (HCC) is associated with chronic inflammation and fibrosis arising
from different etiologies, including hepatitis B and C and alcoholic and nonalcoholic fatty …

Liver cancer is the second leading cause of cancer mortality worldwide, causing more than
700,000 deaths annually. Because of the wide landscape of genomic alterations and limited …

Hepatocellular carcinoma (HCC) is one of the most aggressive types of cancer and lacks
effective therapeutic approaches. Most HCC develops in the setting of chronic liver injury …

Cancer associated fibroblasts (CAF) and the extracellular matrix (ECM) produced by them
have been recognized as key players in cancer biology and emerged as important targets …

The prostaglandins constitute a family of lipids of 20 carbon atoms that derive from
polyunsaturated fatty acids such as arachidonic acid. Traditionally, prostaglandins have …

Hepatocellular carcinoma (HCC) is among the most lethal and prevalent cancers in the
human population. Different etiological factors such as hepatitis B and C virus, alcohol and …

Chronic liver injury due to viral hepatitis, alcohol abuse, and metabolic disorders is a
worldwide health concern. Insufficient treatment of chronic liver injury leads to fibrosis …

The Warburg effect, one of the hallmarks of tumors, produces large amounts of lactate and
generates an acidic tumor microenvironment via using glucose for glycolysis. As a …